Leest u ook de recent toegevoegde informatie over dr. Robert Gorter en het Medical Center Cologne onder deze informatie: Mijn ervaringen met dr.Robert Gorter en het Medisch Centrum Keulen. Een waarschuwing 

En Klik hier voor meer adressen van klinieken in Duitsland waar dendritische celtherapie wordt gegeven.

Interessant is ook dit studierapport: Dendritic cell therapy for oncology roundtable conference: This report does not cover all presentations, but aims to highlight selected points of interest, particularly relating to possible limitations and potential approaches to improvement of DC therapies specifically, and also immunotherapeutic interventions in general terms.

Literatuurlijst van studies met dendritische celtherapie d.d. 2005. Zie verder op deze pagina voor recentere studies:

1. Steinmann RM: The dendritic cell system and its role in immunogenicity.Ann Rev. Immunol. (1991) 9:271-296
2. Fan Z, Huan XL, Borowski L, Mellors JW, Rinaldo CR: Restoration of anti-human immunodeficiency virus type 1 (HIV-1) responses in CD8+ T cells from late-stage patients on prolonged antiretroviral therapy by stimulation in vitro with HIV-1 protein-loaded dendritic cells. J Virol (2001) May, 75(9): 4413-4419
3. Caux C et al: GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature (1992) 360: 258-261
4. Santiago-Schwarz F et al: TNF in combination with GM-CSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages.J Leukoc Biol (1992) 52: 274-281
5. Herbst B et al: In vitro differentiation of CD34+ hematopoietic progenitor cells toward distinct dendritic cell subsets of the birbeck granule and MIIC- positive Langerhans cell and the interdigitating dendritic cell type.Blood (1996) 88: 2541-2548
6. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.J Exp Med. (1994) 179: 1109-1118
7. Peters J et al: Dendritic cells: From ontogenetic orphans to myelo-monocytic descendants. Immunol Today (1996) 17:273-278
8. Mayordomo J et al: Bone Marrow-Derived Dendritic Cells Serve as Potent Adjuvants for Peptide-Based Antitumor Vaccines.Stem cells (1997) 15: 94-103
9. Hsu FJ et al: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 2: 52-58
10. Dietz AB, Litzow MR, Gastineau DA, Vuk-Pavlovic S: Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukaemia. Croat Med J (2001) 42(4): 427-434
11. Sangro B, Qian C, Schmitz V, Prieto J: Gene therapy of hepatocellular carcinoma and gastrointestinal tumors. Ann NY Acad Sci (2002); 963: 6-12.
12. Qiu S, Ye S, Tang Z, Qian S, Li L: Feasibility of using hepatitis B virus surface antigen as target antigen in immunogeng therapy against cancer. Zhonghua Yi Xue Za Zhi (2002) 82: 253-256.
13. Liu B, Ye S, He P, Zheng N, Zhao, Sun R, Tang Z: Study of the cytotoxicity against human hepatocellular carcinoma cells induced by the MAGE-1 gene modified dendritic cells. Zhonghua Gan Zang Bing Za Zhi (2001) 9: 151-153.
14. Liu B, Ye S, He P, Xue Q, Gao D, Tang Z: Antitumor activities in vivo of interleukin-12 gene modified dendritic cells in murine models. Zhonghua Gan Zang Bing Za Zhi (2000) 8: 350-351.
15. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N, Kipps TJ, Choi YS, Bennetti F, Reed JC: Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood (2002) Sep 1;100(5):1795-1801.
16. Ruffini PA, Kwak LW: Immunotherapy of multiple myeloma. Semin Hematol (2001) 38:260-267.
17. Gong J, Koido S, Chen A, Tanaka Y, Huang L, Avigan D, Anderson K, Ohno T, Kufe D: Immunization against murine multiple myeloma with infusions of dendritic and plasmacytoma cells is potentiated by interleukin-12. Blood (2002) 99:2512-2517.
18. Liu Y, Zhang W, Chan T, Saxena A, Xiang J: Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Lek Res (2002) 26:757-763.
19. Zeis M, Frenzke H, Schmitz N, Uharek L, Steinmann J: Idiotype protein-pulsed dendritic cells produce strong ant-myeloma effects after syngeneic stem cell transplantation in mice. Bone Mattow Transplant (2002) 29:213-221.
20. Cull GM, Timms JM, Haynes AP, Russell NH, Irving WL, Ball JK: Dendritic cells cultured from mononuclear cells and CD34 cells in myeloma do not harbour human herpes virus 8. Br J Haematol (1998) 100:793-796.
21. Valone FH, Small E, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R: Dendritic cell-based treatment of cancer: closing in on a cellular therapy. (in print).
22. Tanaka F, Yamaguchi H, Ohta M, Mashino K, Sonoda H, Sadanaga N, Inoue H, Mori M: Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. Int J Cancer (2002) Sep 20; 101(3):265-269.
23. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Brostjan C, Jakesz R, Gnant M.: In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells. Int J Oncol. 2003 Mar; 22(3):651-6.
24. Engleman E.G: Dendritic cell-Based cancer immunotherapie. Semin Oncol (2003) 30 (Suppl 8):23-29.
25. Freudenthal PS Engleman EG: The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci U S A 87: 7698-7702, 1990.
26. Markowicz S, Englenman EG: Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 85: 9555-961, 1990.
27. Mehta-Damani A, Markowicz S, Englenman EG: Generation of antigen-specific CD8+ CTLs from naïve precursors. J immunol 153:996-1003, 1994.
28. Mehta-Damani A, Markowicz S, Englenman EG: Generation of antigen-specific CD4+ T cell lines from naïve precursors. J immunol 25: 1206-1211, 1995.
29. Hsu FJ, Benike C, Fagnone F, et al: Vaccination of patients with B cell lymphoma using autolugus antigen-pulsed dendritic cells. Nature Med 2:52-58, 1996.
30. Timmerman JM, Czerwinski DK, Davis TA, et al: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 99:1517-1526, 2002.
31. Liso A, Stocherl-Goldstein KE, Auffermann-Gretzinger S, et al: Idiotype vaccination using dendritic cells after autolugus peripheral blood progenitor cell trasplnatation for multiple myeloma. Biol Blood Marrow transplant 6:621-627, 2000.
32. Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, et al: The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. Journal of Neuro-Oncology 64: 161-176, 2003.
33. Patrone F, Valbonesi M, Ballestrero Alberto: Autologous peripheral blood stem cells (PBSC) in breast cancer. Transfunsion and apheresis science 27 (2002) 167-173.
34. Office for national statistics, Morality, statistics, cause No 21, DH2 series, HMSO, 1996.
35. Wojas K, Tabarkiewicz J, Jankiewicz M, Rolinski J: Dendritic cells in peripheral blood of patients with breast and lung cancer a pilot study. Folia Histochem Cytobiol. 2004; 42(1): 45-8.
36. Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, Gendler SJ, Mukherjee P.Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol. 2004 Mar;11(3):328-39.
37. Manna PP, Jaramillo A, Majumder K, Campbell LG, Fleming TP, Dietz JR, Dipersio JF, Mohanakumar T: Generation of CD8+ cytotoxic T lymphocytes against breast cancer cells by stimulation with mammaglobin-A-pulsed dendritic cells. Breast Cancer Res Treat. 2003 May;79(1):133-6.
38. Paradoll DM. Topalian SL: The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 10: 588-594, 1998.
39. Bigotti G, Coli A, Castagnola D: Distribution of Langerhans cells and HLA class II molecules in prostatic carcinomas of different histopathological grade. Prostate. 1991;19(1):73-87.
40. Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy G. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate. 1996 Jan;28(1):65-9.
41. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A.Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. 1996 Dec;29(6):371-80.
42. Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Boynton AL, Murphy GP: Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate. 1997 Sep 1;32(4):272-8.
43. Slovin SF, Kelly WK, Scher HI: Immunological approaches for the treatment of prostate cancer. Semin Urol Oncol. 1998 Feb; 16(1):53-9. Review
44. Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, Kenny GM, Rogers M, Boynton AL, Murphy GP.: Report of immune Monitoring of prostate cancer patients undergoing T-Cell therapy using dendritics cells pulsed with HLA-A2-Specific peptides from prostate-specific membrane antigen (PSMA). The Prostate 35:144-151 (1998).
45. Salgaller ML, Tjoa BA, Lodge PA, Ragde H, Kenny G, Boynton A, Murphy GP.Dendritic cell-based immunotherapy of prostate cancer. Crit Rev Immunol. 1998;18(1-2):109-19.
46. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP: Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate. 1998 Jun 15;36(1):39-44.
47. Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC.Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate. 1998 Jul 1;36(2):129-38.
48. Simmons SJ, Tjoa BA, Rogers M, Elgamal A, Kenny GM, Ragde H, Troychak MJ, Boynton AL, Murphy GP: GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate. 1999 Jun 1;39(4):291-7.
49. Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, Murphy GP: Follow-up evaluation of a phase II prostate cancer vaccinetrial.Prostate. 1999 Jul 1;40(2):125-9.
50. Murphy GP, Snow P, Simmons SJ, Tjoa BA, Rogers MK, Brandt J, Healy CG, Bolton WE, Rodbold D: Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients.Prostate. 2000 Jan;42(1):67-72.
51. McNeel DG, Disis ML: Tumor vaccines for the management of prostate cancer. Arch Immunol Ther Exp (Warsz). 2000;48(2):85-93. Review.
52. Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa E, Vieweg J. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol. 2000 May 15;164(10):5508-14.
53. Meidenbauer N, Harris DT, Spitler LE, Whiteside TL. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.Prostate. 2000 May 1;43(2):88-100.
54. Pirtskhalaishvili G, Shurin GV, Gambotto A, Esche C, Wahl M, Yurkovetsky ZR, Robbins PD, Shurin MR: Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J Immunol. 2000 Aug 15;165(4):1956-64.
55. Tjoa BA, Murphy GP: Development of dendritic-cell based prostate cancer vaccine. Immunol Lett. 2000 Sep 15;74(1):87-93. Review.
56. Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, Palucka KA: Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol. 2000 Oct 1; 165(7):3797-803.
57. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000 Dec 1;18(23):3894-903.
58. Pirtskhalaishvili G, Nunez A, Esche C, Shurin GV, Huland E, Huland H, Shurin MR: Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate. 2001 Jan 1;46(1):68-75.
59. Mincheff M, Altankova I, Zoubak S, Tchakarov St, Btoev Ch, Petrov St, Krusteva G, Kurtev P, Dimitrov V, Ilieva M, Georgiev G, Lissitchkov T, Chernozemski Iv, Meryman HT: In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotheraphy of cancer _Changues in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):125-32.
60. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol. 2001 Dec 15;167(12):7150-6.
61. Kiessling A, Schmitz M, Stevanovic S, Weigle B, Holig K, Fussel M, Fussel S, Meye A, Wirth MP, Rieber EP. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer. 2002 Dec 1;102(4):390-7.
62. Engleman EG: Dendritic cell-based cancer immunotherapy. Semin Oncol. 2003 Jun; 30(3 Suppl 8):23-9. Review.
63. Ciavarra RP, Brown RR, Holterman DA, Garrett M, Glass WF 2nd, Wright GL Jr, Schellhammer PF, Somers KD. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Cancer Immunol Immunother. 2003 Jun 24 [Epub ahead of print].
64. Zhang S, Zeng G, Wilkes DS, Reed GE, McGarry RC, Eble JN, Cheng L. Dendritic cells transfected with interleukin-12 and pulsed with tumor extract inhibit growth of murine prostatic carcinoma in vivo. Prostate. 2003 Jun 1;55(4):292-8.
65. Kiessling A, Fussel S, Schmitz M, Stevanovic S, Meye A, Weigle B, Klenk U, Wirth MP, Rieber EP. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. Prostate. 2003 Sep 1;56(4):270-9.
66. Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, Albertsen PC. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother. 2003 Aug;52(8):497-505. Epub 2003 Jun 03.
67. Wolchok JD, Gregor PD, Nordquist LT, Slovin SF, Scher HI: DNA vaccines: an active immunization strategy for prostate cancer. Semin Oncol. 2003 Oct;30(5):659-66. Review.

Plaats een reactie ...

Reageer op "Literatuurlijst van studies met dendritische celtherapie."

Gerelateerde artikelen

Gerelateerde artikelen

Genezing met warmte: Amerikaans >> Dendritische celtherapie begeleidt >> Dr. Figdor werkzaam in de >> Literatuurlijst van studies >> Medical Center Cologne - Dr. >> Onderzoek en dendritische >> Prof. dr. Yvette van Kooyk >> Succes en belofte van dendritische >> Vaccinatie tegen kanker. Nijmeegse >> Algemeen: Dendritische celtherapie >>